Dr. Mehanna on the Design of the De-ESCALaTE Trial in HPV+ Head and Neck Cancer
April 11th 2019Hisham Mehanna, PhD, BMedSc, MBChB, FRCS, chair, Head and Neck Surgery, director, Institute of Head and Neck Studies and Education at the Institute of Cancer and Genomic Sciences, University of Birmingham, discusses the design of the De-ESCALaTE trial in patients with HPV-positive head and neck cancer.
Read More
Dr. Mehanna on Goals of the Updated Staging System in HPV+ Head and Neck Cancer
February 27th 2019Hisham Mehanna, PhD, BMedSc, MBChB, FRCS, chair, Head and Neck Surgery director, Institute of Head and Neck Studies and Education at the School of Cancer Studies, University of Birmingham, discusses goals of the updated staging system in HPV-positive head and neck cancer.
Read More
Dr. Mehanna on Implications of the Updated Staging System for HPV+ Head and Neck Cancer
January 29th 2019Hisham Mehanna, PhD, BMedSc, MBChB, FRCS, chair, Head and Neck Surgery director, Institute of Head and Neck Studies and Education at the School of Cancer Studies, University of Birmingham, discusses the implications of the updated staging system for patients with HPV-positive head and neck cancer.
Read More
Dr. Mehanna on the Updated Staging System for HPV+ Head and Neck Cancer
October 25th 2018Hisham Mehanna, PhD, BMedSc, MBChB, FRCS, chair, Head and Neck Surgery director, Institute of Head and Neck Studies and Education at the School of Cancer Studies, University of Birmingham, discusses the new staging system for patients with HPV-positive head and neck cancer.
Read More